Identify obstructive sleep apnoea using only a smartphone

ResApp has developed an obstructive sleep apnoea screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.

Sleep apnoea is the most common sleep breathing disorder affecting more than three in every ten men and nearly two in every ten women. Sleep apnoea is when air stops flowing to your lungs for ten seconds or longer during sleep. In some cases, this can happen more than 30 times per hour.

Studies have shown that 80% of people with sleep apnoea are undiagnosed. Sleep apnoea is today diagnosed by an overnight sleep study, often in a sleep laboratory using polysomnography (PSG). During PSG, a large number of contact sensors are used to monitor heart, lung and brain activity, breathing patterns, arm and leg movements, and blood oxygen levels whilst asleep. Patients find this uncomfortable and have difficulty sleeping in this unfamiliar environment.

Our solution requires only a smartphone placed on the bedside table. Our machine-learning algorithms analyse overnight breathing and snoring sounds to identify obstructive sleep apnoea (OSA). Results from a prospective, double-blind clinical study achieved 84% sensitivity and 83% specificity for identifying mild, moderate or severe OSA (AHI ≥ 5/h) compared to simultaneous in-laboratory PSG on a cohort of 582 patients.

Read about our prospective clinical study results

Scientific Presentations & Publications

Partridge N, May J, Peltonen V, Wood, J, Keating T, Abeyratne U, Currie P, Lenstra S, Ling I, Large sample feasibility study showing smartphone‐based screening of sleep apnoea is accurate compared with polysomnography, Sleep DownUnder 2018, the 30th ASM of the Australasian Sleep Association and the Australasian Sleep Technologists Association, 2018.

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.